The 2023-2028 World Outlook for Arthiritis Therapeutics

This study covers the world outlook for arthiritis therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of t...

5/10/2022 | ovarian cancer drugs and diagnostics

The 2023-2028 World Outlook for App Analytics

This study covers the world outlook for app analytics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region,...

5/10/2022 | sepsis drugs

The 2023-2028 World Outlook for Antiviral Drugs

This study covers the world outlook for antiviral drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the regio...

5/10/2022 | antiviral drugs

The 2023-2028 World Outlook for Antithrombotic Drugs

This study covers the world outlook for antithrombotic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the ...

5/10/2022 | antithrombotic drugs

The 2023-2028 World Outlook for Antiemetic Drugs

This study covers the world outlook for antiemetic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the regi...

5/10/2022 | antiemetic drugs

The 2023-2028 World Outlook for Anticoccidial Drugs

This study covers the world outlook for anticoccidial drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the r...

5/10/2022 | anticoccidial drugs

The 2023-2028 World Outlook for Anticoagulants

This study covers the world outlook for anticoagulants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region...

5/10/2022 | Parkinson's disease drugs

The 2023-2028 World Outlook for Antibody Drugs

This study covers the world outlook for antibody drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region...

5/10/2022 | antibody drugs

The 2023-2028 World Outlook for Anti-Smoking Drugs

This study covers the world outlook for anti-smoking drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the re...

5/10/2022 | anti-smoking drugs

The 2023-2028 World Outlook for Anti-Obesity Drugs

This study covers the world outlook for anti-obesity drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the re...

5/10/2022 | anti-obesity drugs

This study covers the world outlook for arthiritis therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of arthiritis therapeutics as including all commonly understood products and/or services falling within this broad category, such as smart glass for cars, trucks, and public transportation active self-dimming windows self-cleaning and self-repairing glass and photovoltaic technologies, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for app analytics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of app analytics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include adjust, Adobe, Amazon Web Services, Inc., Amplitude, App Annie, Appscatter, AppSee, Appsflyer, Apptentive, Clevertap, Contentsquare, Countly, Google, Heap, IBM, Kochava, Localytics, Mixpanel, MoEngage, Segment, Swrve, Taplytics, Tune, WizRocket, Inc., and Yahoo. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for antiviral drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antiviral drugs as including all commonly understood products falling within this broad category, such as brakes, rotors, brake pads, calipers, and parts and brake pads and brake shoes, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, AbbVie, Alembic Pharmaceuticals, Amneal Pharmaceuticals, Aurobindo Pharma, Bausch Health, Bristol-Myers Squibb, Cipla, Dr. Reddy’s Laboratories, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Hetero, Janssen Pharmaceuticals, Johnson & Johnson, Laurus Labs, Lupin, MedImmune, Merck, Micro Labs,, Mylan NV, Novartis, Roche Diagnostics, Schering-Plough, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Zydus Pharma. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for antithrombotic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antithrombotic drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Aspen Holdings, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Dr. Reddy’s Laboratories, Eisai Company, Eli Lilly and Company, F. Hoffmann-La Roche, Fresenius Kabi, Genentech, Hebei Changshan Biochemical Pharmaceutical Company, Hikma Pharmaceuticals, Johnson & Johnson, Mylan NV, Nanjing Jianyou Biochemical Pharmaceutical Company, Novartis, OPOCRIN, Otsuka, Pfizer, Pharmacia, Inc., Sanofi, SARIA SE & Company, Shanghai Fosun Pharmaceutical, Shenzhen Hepalink Pharmaceutical Group Company, Teva Pharmaceutical Industries, The Medicines Company, Watson Laboratories, Inc., Yino Pharma, and Zydus Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for antiemetic drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antiemetic drugs as including all commonly understood products falling within this broad category, such as premium payments for advertising, data transport, and subscriptions, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Astellas Pharma, Astra Zeneca, Baxter International, Charleston Laboratories, Cipla, GlaxoSmithKline, Johnson & Johnson, Merck, Neurowave Medical Technologies, Novartis, Pfizer, Sanofi-Aventis U.S., and Schering Plough. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anticoccidial drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anticoccidial drugs as including all commonly understood products falling within this broad category, such as anti-ageing devices for Generation X, Y, and baby boomers, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Boehringer, Elanco, Huvepharma, Merck, Merial, Vetoquinol, Virbac, and Zoetis. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anticoagulants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anticoagulants as including all commonly understood products falling within this broad category, such as equipment used in vehicle production, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott India, Aspen Holdings, Bayer, Boehringer Ingelheim, Bristol Myers squibb Company, Eisai Company, F. Hoffmann-La Roche, Fresenius Kabi, GlaxoSmithKline, Hebei Changshan Biochemical Pharmaceutical Company, Hikma Pharmaceuticals, Janssen Pharmaceuticals, Mitsubishi Tanabe Pharma, Mylan NV, Nanjing Jianyou Biochemical Pharmaceutical Company, Novartis, OPOCRIN, Pfizer, Sanofi, SARIA SE & Company, Shanghai Fosun Pharmaceutical, Shenzhen Hepalink Pharmaceutical Group Company, Teva Pharmaceutical Industries, and Yino Pharma. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for antibody drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of antibody drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, AbbVie, Amgen, Biogen, Johnson & Johnson, Merck, Novartis, Roche, Takeda Pharmaceutical, and UCB. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anti-smoking drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-smoking drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Aradigm, Celtic Pharma, GlaxoSmithKline, Johnson & Johnson, Novartis, and Selecta Biosciences. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

This study covers the world outlook for anti-obesity drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of anti-obesity drugs as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, ADial Pharmaceuticals, AEMPS, AIFA, Akrimax Pharmaceuticals, Alizyme, American Medical Association, Amylin Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Biophytis, Boehringer Ingelheim, Boston Therapeutics, Diasome, Eisai, EMEA, Empros Pharma, F. Hoffmann-La Roche, FDA, G-BA, GenePreDiT, GlaxoSmithKline, Hanmi, HAS, Ildong Pharmaceuticals, Intarcia Therapeutics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, KT&G Life Sciences, KVK TEch, Kwang Dong, Medivation, Medlab Clinical, Neothetics, NGM Biopharmaceuticals, NICE, Novartis, Novo Nordisk, OPKO Health, Orexigen, Rhythm Pharmaceuticals, Roche, Saniona, Shionogi & Company, SMC, Takeda, Teva, Valeant Pharmaceuticals, Virtici, Vivus, World Health Organization (WHO), Xenetic Biosciences, and Zafgen. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

5/10/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT